Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686

BACKGROUND: ACRIN 6686/RTOG 0825 was a phase III trial of conventional chemoradiation plus adjuvant temozolomide with bevacizumab or without (placebo) in newly diagnosed glioblastoma. This study investigated whether changes in contrast-enhancing and fluid attenuated inversion recovery (FLAIR)–hyperi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: Boxerman, Jerrold L, Zhang, Zheng, Safriel, Yair, Rogg, Jeffrey M, Wolf, Ronald L, Mohan, Suyash, Marques, Helga, Sorensen, A Gregory, Gilbert, Mark R, Barboriak, Daniel P
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2018
Gaiak:
Neuroimaging
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6120359/
https://ncbi.nlm.nih.gov/pubmed/29590461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy049
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak